TXP Innovations LLC dba Tex Peptides — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
On August 24, 2026, the FDA Center for Drug Evaluation and Research (CDER) issued Warning Letter 735067 to TXP Innovations LLC dba Tex Peptides (CEO Felicia Romero, Dallas, TX) for offering unapproved new drugs via website texpeptide.com, including Semaglutide, Tirzepatide, Retatrutide, SS-31, Tesamorelin, PT-141, and Bacteriostatic Water with Benzyl Alcohol, in violation of sections 301(d) and 505(a) of the FD&C Act. The FDA documented that website labeling made disease-treatment and metabolic-function claims for these products, establishing drug intent under section 201(g)(1) of the FD&C Act, and flagged injectable products as posing particular public health risk due to direct body delivery bypassing natural defenses.
Argus analysis
# FDA Warning Letter Analysis: TXP Innovations LLC dba Tex Peptides
**The Company and Violations**
TXP Innovations LLC, operating as Tex Peptides and based in Dallas, Texas, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on August 24, 2026. The agency reviewed the company's website (texpeptide.com) in July 2026 and identified seven products marketed as unapproved new drugs: Semaglutide (GLP-1 SEM), Tirzepatide (GLP-2 TRZ), Retatrutide (GLP-3 RT), SS-31 (Elamipretide), Tesamorelin, PT-141 (Bremelanotide), and Bacteriostatic Water with benzyl alcohol. The FDA emphasized particular concern regarding injectable products, which bypass the body's natural defenses and carry risks of serious harm including infection and systemic toxicity.
**Regulatory Citations and Meaning**
The violations cite sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(d) and 355(a)), along with the definition of "new drugs" under section 201(p) (21 U.S.C. 321(p)). These provisions require FDA approval before marketing drugs intended to diagnose, treat, mitigate, or prevent disease, or affect body structure or function. The company's website labeling explicitly described therapeutic uses—glucose regulation for diabetes, weight loss, cardiovascular health, mitochondrial function, and sexual dysfunction—establishing drug intent despite "research use only" disclaimers. The FDA determined these products lack recognized safety and efficacy and possess no approved New Drug Applications.
**Response Timeline and Industry Watchpoints**
Tex Peptides must submit a written response within 15 business days to FDAAdvisory@fda.gov detailing corrective actions and preventive measures. Compliance officers monitoring similar operations should expect continued FDA enforcement against online peptide vendors using disclaimer language to circumvent approval requirements. Regulatory risk intensifies given injectable product delivery and direct health claims. The warning letter signals FDA's focus on unapproved GLP-1 receptor agonists and emerging peptides marketed through digital channels. Non-compliance may trigger seizure or injunction actions.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER TXP Innovations LLC dba Tex Peptides MARCS-CMS 735067 — August 24, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Recipient Name Felicia Romero Recipient Title CEO TXP Innovations LLC dba Tex Peptides 539 West Commerce Street Dallas , TX 75208-1953 United States support@texpeptide.com texpeptides@gmail.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 24, 2026 WARNING LETTER Reference Number: 735067 To Felicia Romero: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions. FDA Review Violations were identified and documented during a review of your website texpeptide.com in July 2026. Based on our review, “Semaglutide (GLP-1 SEM),” “Tirzepatide (GLP-2 TRZ),” “Retatrutide (GLP-3 RT),” “SS-31 (Elamipretide),” “Tesamorelin,” “PT-141 (Bremelanotide),” and “Bacteriostatic Water 0.9% Benzyl Alcohol (10 ml)” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations. Unapproved New Drug Violations Based on a review of your website,“Semaglutide (GLP-1 SEM),” “Tirzepatide (GLP-2 TRZ),” “Retatrutide (GLP-3 RT),” “SS-31 (Elamipretide),” “Tesamorelin,” “PT-141 (Bremelanotide),” and “Bacteriostatic Wat…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was TXP Innovations LLC dba Tex Peptides cited for?
- The FDA Warning Letter to TXP Innovations LLC dba Tex Peptides (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs/Misbranded. Classification: Unapproved drug.
- When did FDA issue the warning letter to TXP Innovations LLC dba Tex Peptides?
- FDA issued the letter (MARCS-CMS 735067) on 2026-08-24 and posted it publicly on fda.gov on 2026-09-01.
- Is the FDA warning letter to TXP Innovations LLC dba Tex Peptides publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). TXP Innovations LLC dba Tex Peptides — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-txp-innovations-llc-dba-tex-peptides-2026-08-24-unapproved-drug
"TXP Innovations LLC dba Tex Peptides — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-txp-innovations-llc-dba-tex-peptides-2026-08-24-unapproved-drug.
Argus HQ Research. "TXP Innovations LLC dba Tex Peptides — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded." Digital Empire Holdings LLC. Accessed September 2, 2026. https://argushq.ai/fda/warning-letter/fda-wl-txp-innovations-llc-dba-tex-peptides-2026-08-24-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_txp_innovations_llc_dba_tex_peptides_2026_08_24_unapproved_drug_2026,
title = {TXP Innovations LLC dba Tex Peptides — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-txp-innovations-llc-dba-tex-peptides-2026-08-24-unapproved-drug},
note = {Accessed: September 2, 2026}
}